natgillin/translations-raw huggingface dataset:
An aqueous pharmaceutical composition with a pH between 3.4 and 4.6 comprising insulin glargine for use in a method of providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus, wherein the composition comprises 270 - 330 U/mL of insulin glargine. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
The apparatus of claim 5 wherein said needle cassette further comprises means (209, 210, 211, 588, 622) for permitting rotation of the body in only one direction. 
Aparatura u skladu s patentnim zahtjevom 5, naznačen time što navedena kazeta za igle nadalje sadržava sredstvo (209,210, 211, 588, 622) koje dopušta rotiranje tijela samo u jednom smjeru.
The method includes: a core encoding step in which the speech encoding device encodes a low frequency component of the speech signal; a temporal envelope supplementary information calculating step in which the speech encoding device calculates temporal envelope supplementary information for obtaining an approximation of a temporal envelope of a high frequency component of the speech signal by using a temporal envelope of a low frequency component of the speech signal; and a bit stream multiplexing step in which the speech encoding device generates a bit stream in which at least the low frequency component encoded in the core encoding step and the temporal envelope supplementary information calculated in the temporal envelope supplementary information calculating step are multiplexed. 
Postupak dekodiranja govora u kojem se upotrebljava naprava za dekodiranje govora za dekodiranje kodiranog govornog signala, naznačen time što se postupak dekodiranja govora sastoji u: koraku osnovnog dekodiranja, u kojem naprava za dekodiranje govora dekodira struju bitova koja sadrži kodirani govorni signal kako bi se dobilo niskofrekventnu komponentu, gdje struja bitova dolazi izvan naprave za dekodiranje govora; koraku pretvorbe frekvencije, u kojem naprava za dekodiranje govora pretvara niskofrekventnu komponentu dobivenu u koraku osnovnog dekodiranja u frekventno područje;
units represent at least one optionally present substitutions for a ring hydrogen atom; or two R10 units can be taken together to form a substituted or unsubstituted C4-C8 cycloalkyl ring, a substituted or unsubstituted C6 or C10 aryl ring, a substituted or unsubstituted C2-C8 heterocyclic ring, or a substituted or unsubstituted C3 to C5 heteroaryl ring, wherein the heterocyclic and heteroaryl rings comprise one or more hetero atoms independently chosen from oxygen (O), nitrogen (N), or sulfur (S). 
or C10, supstituirani ili nesupstituirani C2-C8 heterociklični prsten, ili supstituirani ili nesupstituirani C3 do C5 heteroaril prsten, pri čemu heterociklični i heteroarilni prsteni obuhvaćaju jedan ili više hetero atoma neovisno odabranih između kisika (O), dušika (N), ili sumpora (S).
The crystallizing may occur at a temperature that ranges from about -10°C to about +40°C and all temperature values in between. 
Postupak iz patentnog zahtjeva 1, u kome se kristalizacija događa na temperaturi koja je u opsegu od -10"C€ do +40"C.
The automatic analyzer according to claim 3, wherein the abnormality specifying section specifies that the reaction liquid of the reaction container is abnormal when the number of the standard deviations smaller than the threshold is 1 or below. 
Postupak prema zahtjevu 11, naznačen time da (v) određuje da je reakcijska tekućina (W) iz reakcijskog spremnika (20) abnormalna kada se mnoštvo standardnih devijacija smanjuje tijekom vremena i broj standardnih devijacija koji ne prelazi prag (LT) je 1 ili manje.
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein: ring A is independently selected from 
(V) ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje: prsten A je nezavisno odabran od
The method of claims 18 to 19, wherein the liquid coating formulation used to form an absorptive layer and/or a topcoat has a solid content of 10 to 80 wt.-%, preferably of 30 to 60 wt.-%, and more preferably of 45 to 55 wt.-% based on the total weight of the formulation. 
Postupak prema zahtjevima 17 ili 18, naznačen time da tekuća formulacija premaza koji se koristi za dobivanje apsorpcijskog sloja i/ili završnog premaza koji ima sadržaj krutih tvari od 10 do 80 tež-%, poželjno od 30 do 60 tež-%, i poželjnije od 45 do 55 tež-% u odnosu na ukupnu težinu formulacije. HR P20150377 T1
Equipment for controlling, measuring and reporting a physical quantity of a container containing a fluid under pressure according to the previous claims characterized in that the dosing knob (S1.1) is positioned adjacent to the electronic circuit (S1.3). 
Metoda za kontroliranje, mjerenje i izvještavanje vrijednosti brzine toka fluida koja je određena pomoću opreme za kontroliranje, mjerenje i izvještavanje fizičke veličine posude koja sadrži fluid pod pritiskom za koju se traži zaštita u prethodnim patentnim zahtjevima okarakterizirana time da:
The method according to claim 1, in which the raw materials are added dry. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se sirovine dodaju suhe.
the heavy chain Fv fragment of a monovalent Fab forming the antigen-binding domain is linked to one of the polypeptides forming the Fc domain via a CH1 domain; the light chain Fv fragment of the Fab is linked to a CL domain; the heavy chain Fv fragment of the Fab forming the CD3-binding domain is linked to the other polypeptide forming the Fc domain via a CL domain; and the light chain Fv fragment of the Fab is linked to a CH1 domain; 
(iii) Fv fragment teškog lanca jednovalentnog Fab koji tvori domenu za vezanje na antigen je vezan na jedan od polipeptida koji tvore Fc domenu preko domene CH1; Fv fragment lakog lanca Fab je vezan na domenu CL; Fv fragment teškog lanca Fab koji tvori domenu za vezanje na CD3 je vezan na drugi polipeptid koji tvori Fc domenu preko domene CL; i Fv fragment lakog lanca Fab je vezan na domenu CHI;
The fuel of claim 10, wherein: the cellulosic biomass comprises wood or wood residues; ii) the unenriched renewable fuel oil feedstock has a solids content of less than 0.5 wt. % and an ash content of less than 0.1 wt. %; and 
Postupak prema jednom od zahtjeva 1 do 6, naznačen time što: 1) celulozna biomasa sadrži otpatke šećerne trske, palmino lišće ili prazne voćne grozdove; 1 1i) neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt. % i sadržaj pepela od manje od 0,1 wt.
to 50 wt.%, particularly 1 to 50 wt.%, preferably 10 to 40 wt.% and more preferably 15 to 30 wt.% of said release modifying material; 
do 50 masenih %, posebno 1 do 50 masenih %, poželjno 10 do 40 masenih % i najpoželjnije 15 do 30 masenih % navedenog materijala koji modificira oslobađanje;
In yet another embodiment, the anti-myostatin Adnectin of the present invention comprises an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the non-BC, DE, and FG loop regions of SEQ ID NO: 273, 118, or 281. 
Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži aminokiselinski slijed najmanje 80 %, 85 %, 90 %, 95 %, 98 %, 99 % ili 100 % istovjetan područjima koja nisu petlje BC, DE, te FG u SEQ ID NO: 331, 273, 281 ili 115.
The micro chip (10) as claimed in claim 1, wherein there is a gap between the reaction chamber (11) base and the heater (12), and said gap is ranging from about 0.2 mm to about 0.7 mm. 
Mikročip (10) prema zahtjevu 1, pri čemu se između reakcijske komore (11) baze 1 grijača (12) nalazi praznina veličine od 0,2 mm do 0,7 mm.
The disorder can be, for example, arthritis, including chronic rheumatoid arthritis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; systemic lupus erythematosus; and inflammatory diseases. 
Uporaba u skladu s patentnim zahtjevom 10 ili antitijelo ili fragment u skladu s patentnim zahtjevom 11, naznačena time, da je navedeni artritis kronični reumatoidni artritis, a navedena upalna bolest crijeva Chronova bolest ili ulcerozni colitis.
The method of claim 2, wherein the amount of treprostinil or a pharmaceutically acceptable salt, or derivative thereof which is administered is at least 1.0 ng/kg of body weight. 
11.Pripravak za primjenu u skladu sa zahtjevima 1 do 10, naznačen time što je efektivna količina Treprostinila ili njegove farmaceutski prihvatljive soli najmanje 1.0 ng/kg tjelesne težine.
Synthesis of compound 6 3-chloropropanoyl chloride was esterified with ethanol in the presence of pyridine or triethylacetate to produce ethyl 3-chloropropionate 5. 
Sinteza spoja 6 3-kloropropanoil klorid je csterificiran s ctanolom u prisustvu piridina ili trictilacctata da so dobije ctil 3-kloropropionat 5.
Another disadvantage of known hard lozenges containing sodium carbonate is that the sodium carbonate buffer may decompose at the temperatures required for manufacture. 
Slijedeći nedostatak poznatih tvrdih tableta-pastila koje sadrže natrijev karbonat je taj da natrijev karbonatni pufer se može razložiti na temperaturama koje su potrebne za proizvodnju.
This is advantageous for some applications. 
To ima prednost za neke aplikacije.
The computer system of claim 6, wherein the machine instruction further comprises a mask field, the mask field specifying the boundary. 
Računalni sustav u skladu s patentnim zahtjevom 10., naznačen time što strojna naredba dodatno sadrži polje maske, pri čemu polje maske specificira granicu.
The pharmaceutical composition for use in the prevention of colectomy, according to Item H2, wherein said composition is repetitively administered as a single exposure on separate occasions 4 to 8 weeks apart. 
Oligonukleotid za primjenu prema patentnom zahtjevu 1, naznačen time, što se predmetni oligonukleotid opetovano primjenjuje u obliku jednokratne izloženosti u više navrata u razmaku od 4 do 8 tjedana.
In a further embodiment the polypeptide of the invention elicits a protective immune response in a mammalian host against strains of C. difficile . 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što polipeptid izaziva zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
In some embodiments, the BC loop of the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7-38. 
leucin na položaju 4 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine M i V;
Composition according to any one of claims 1 to 5, wherein the composition comprising the sphingosine 1-phosphate receptor agonist is administered to the subject prior to or after the onset of symptoms of the condition. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da se sastav daje subjektu prije ili poslije nastanka simptoma kronične upalne demijelinacijske polineuropatije. (CIPD).
The composition for use according to claim 23, wherein therapeutically effective amount of crenolanib or a salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed acute myeloid leukemia (AML) subject, to maintain remission, or a relapsed or refractory acute myeloid leukemia (AML) subject. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove soli osigurana kao jedini agens ili u kombinaciji s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
ii) a cytidine deaminase (CDA) substrate drug selected from the group consisting of 5-azacytidine, gemcitabine, arabinosylcytosine (cytarabine, ara-C), tezacitabine, 5-fluoro-2'-deoxycytidine, and cytochlor. 
primjenu lijeka koji je supstrat za CDA sisavcu kojemu je potreban, a koji se izabire iz skupine koja obuhvaća 5-azacitidin, gemcitabin, ara-C, tezacitabin, 5-fluoro- -deoksicitidin, i citoklor.
The compound for use according to any one of Claims 1 to 7, wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je spoj farmaceutski prihvatljiva sol aniona kojeg se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinat, tartarata, fumarata, glikolata ili citrata.
Additional experiments show that the performance of the MEP HYPERCEL® column is similar using material produced in serum free medium or in medium supplemented with serum. 
U dodatnim je eksperimentima pokazano da su performance kolone MEP HyperCel slične u uvjetima kada se koristio materijal proizveden u mediju bez seruma ili u mediju nadopunjenom sa serumom.
reacting the compound of formula 7 with an alkylpropiolate of the formula CH≡CC(O)OR or an alkyl acrylate of the formula CH2=CHC(O)OR wherein R is alkyl in the presence of a Lewis acid to form a compound of formula 8 wherein P is a protecting group, R is alkyl, and the dashed line ------ is a single or double bond; reacting the compound of formula 8 with H2 under hydrogenation conditions to form a compound of formula 9 wherein P is a protecting group and R is alkyl; reacting the compound of formula 9 with an oxidizing agent to form a compound of formula 10 wherein P is a protecting group such as acetyl and R is alkyl; 
PO" 1) Reakciju spoja formule 7 s alkilpropiolatom formule CH=CC(O)OR ili alkil_akrilatom formule CH2=CHC(O)OR pri čemu je R alkil koji u prisutnosti Lewisove kiseline tvori spoj formule 8 pri čemu je P zaštitna grupa, R je alkil, a iscrtkana linija """""" je jednostruka ili dvostruka veza; 2) Reakciju spoja formule 8 s H> pod hidrogenirajućim uvjetima za dobivanje spoja formule 9 pri čemu je P zaštitna grupa, a R je alkil; h) Reakciju spoja formule 9 s oksidirajućim agensom za dobivanje spoja formule 10 pri čemu je P zaštitna grupa kao primjerice acetil, a R je alkil;
wherein HLMIcomp is the HLMI of the polyethylene composition, HLMIvr is the HLMI of the Ziegler-Natta catalyzed polyethylene resin, HLMIpcr is the HLMI of the high density polyethylene, [PCR] is the proportion of the high density polyethylene in the polyethylene composition relative to the total weight of the polyethylene composition such that [PCR]=wt % PCR/100, and wt % PCR is the proportion in weight percent of the high density polyethylene in the polyethylene composition relative to the total weight of the polyethylene composition. 
hi HMLivr HMLlIpcr: HLMicomp = k naznačeno time da HLMIcomp je HLMI polietilenskog sastava, HLMIvr je HLMI neobrađene Ziegler-Natta katalizirane polietilenske smole, HLMIper je HLMI reciklirane polietilenske smole visoke gustoće, [PCR] je razmjer reciklirane polietilenske smole u polietilenskom sastavu u odnosu na ukupnu težinu sastava kao [PVR]= &% PCR/100, 1 0% PCR je razmjer u postotku težine reciklirane polietilenske smole visoke gustoće u polietilenskom sastavu u odnosu na ukupnu težinu sastava.
Compounds according to claim 1, wherein R2 represents a linear or branched (C1-C6)alkoxy group, a hydroxy group or a halogen atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R2 predstavlja ravnu ili razgrananu (C1-C6)alkoksi skupinu, hidroksi skupinu ili atom halogena.
Figure 2A is a perspective view of an exemplary embodiment of an individualized blender container; 
Slika 2A prikaz je primjera ostvarenja samostalne posude za mješalicu;
The method of claim 10, wherein the DNA-targeting RNA comprises one or more of: a phosphorothioate, an inverted polarity linkage, an abasic nucleoside linkage, a locked nucleic acid (LNA), a 2′-substituted sugar moiety, a 2′-O-methoxyethyl modified sugar moiety, a 2′-O-methyl modified sugar moiety, a 2′-O-(2-methoxyethyl) modified sugar moiety, a 2′-fluoro modified sugar moiety, a 2′-dimethylaminooxyethoxy modified sugar moiety, a 2′-dimethylaminoethoxyethoxy modified sugar moiety, a peptide nucleic acid (PNA), a morpholino nucleic acid, and a cyclohexenyl nucleic acid (CeNA). 
Sastav prema bilo kojem od zahtjeva 1, ili 6 do 10, ili 12 do 13, ili postupak u skladu s bilo kojim od zahtjeva 2 do 4, ili 6 do 13, ili garnitura prema bilo kojem od zahtjeva 5 do 10, ili 12 do 13, naznačen/a time, da RNK koja cilja na DNK, obuhvaća jednu ili više modificiranih nukleobaza, modificiranih strukturnih okosnica ili ne-prirodnih internukleozidnih lančanih spojeva, modificirani dio molekule šećera, zaključanu nukleinsku kiselinu (LNA), ili peptidnu nukleinsku kiselinu.
Because of the high number of doses in multi- dose devices, powder adhesion onto the inner walls of the air conduits and the de- agglomeration means must be minimized and/or regular cleaning of these parts must be possible, without affecting the residual doses in the device. 
Zbog većeg broja doza u napravama za više različitih doza mora se minimizirati prijanjanje praška na unutarnje stijenke zračnih vodova i sklopova za raspršivanje i/ili mora postojati način za redovito čišćenje navedenih dijelova, bez utjecaja na preostale doze u napravi.
A compound according to claim 2 in the form of its Form I crystalline polymorph having the following XRPD data: 
Spoj prema patentnom zahtjevu 2, naznačen time da je u obliku kristalnog polimorfa njegovog Oblika I koji ima slijedeće XRPD podatke:
after a successful pressure test, releasing pressure from the first volume; and 
nakon uspješnog tlačnog ispitivanja otpušta se tlak iz prvog volumena (V1), i
is absent when is a double bond, or when is a single bond, N1-R1 and one of Ra or Rb are connected to form a saturated, paritally unsaturated, or unsaturated heterocycle having 5-7 ring members and the other of Ra or Rb may be hydrogen or absent as necessary to accommodate ring unsaturation; and at least one of the following A-D applies: 
R; je odsutan kada je jednostruka veza, N,-R, i jedan od R, ili R, su povezani kako bi tvorili zasićeni, djelomično nezasićeni ili nezasićeni 5-7-eročlami heterociklički prsten, a drugi od R, ili R, može biti vodik ili je po potrebi odsutan zbog nezasićenosti prstena; i gdje vrijedi najmanje jedna od slijedećih točaka A-D:
validating the batch for distribution only if the sample of the batch after stability testing contains not more than a total of 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of the oxidation decomposition products 2-Chloro-6-(1-ethyl- N -methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1H,3H- spiro[5-chloro-1-methylquinoline-2,4-dione-3,3'-[1]ethylindolin-[2]-one], and 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo- N -phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. 
Cc) validaciju šarže za distribuciju, samo ako uzorak šarže nakon ispitivanja stabilnosti ne sadrži više od ukupno 0,1 te2.% produkata oksidacijskog raspadanja N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida, u odnosu na N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid. Postupak prema patentnom zahtjevu 4, naznačen time, da produkt oksidacijskog raspadanja jest 2-kloro-6-(1-etil-
the concentrations of total metal ions (M) and total ligand (L) are greater than 10-6 molar, and more preferably are greater than 10-3 molar; and/or 
su koncentracije ukupnih metalnih iona (M) i ukupnih liganda (L), veće od 10-6 mola, i još bolje su veće od 10-3 mola; i/ili
is selected from the group consisting of 
Y! je odabran iz skupine koju čine
represents CR4 or nitrogen and 
A3 predstavlja CR4 ili dušik i
The method of claim 6 wherein the heated dilution water is directed into the hydrolyzed sludge during a startup period in the method. 
Postupak prema patentnom zahtjevu 4 naznačeno time da se zagrijana voda za razrjeđivanje usmjerava u hidrolizirani mulj tijekom perioda pokretanja u postupku.
For example, such a medium can include a storage means such as a ROM, for example a CD-ROM or a microelectronic circuit ROM, or a magnetic recording means, for example a floppy disk or a hard disk. 
Nosač u skladu s patentnim zahtjevom 3, naznačen time što takav nosač može sadržavati sredstvo za spremanje, primjerice ROM, CD ROM, ROM na bazi mikroelektronskog kruga ili magnetsko sredstvo za bilježenje, primjerice disketu ili tvrdi disk.
Additionally the inlet side 22 of the thermoblock 10 can be selectively put in fluid connection with (optional) condensing means 15 such that the inlet side 22 of the steam-producing thermoblock 10 is in fluid communication with an evacuation outlet 21. 
Uz to, izlaznu stranu 22 termobloka 10 može se selektivno staviti u fluidni kontakt s (izbornim) kondenzatorom 15, tako da je izlazna strana 22 termobloka za dobivanje vodene pare 10 u fluidnom kontaktu s izlazom za pražnjenje 21.
A peptide mixture according to any one of claims 1-7, a T-cell mixture according to claim 8 or a pharmaceutical composition according to claim 9, for use in the prophylaxis and/or treatment of cancer. 
Peptidna smjesa u skladu sa bilo kojim od patentnih zahtjeva 1-3, smjesa T stanica u skladu sa patentnim zahtjevom 4 ili farmaceutska kompozicija u skladu sa patentnim zahtjevom 5 za primjenu u profilaksi i/ili liječenju raka kod pacijenta.
In a further preferred embodiment, the polymer compounds of the invention are used as active agents for the prevention, alleviation and/or treatment of RAGE-related pathologies. RAGE-related pathologies are defined as pathological states associated with an increased expression of RAGE. 
Uporaba polimernog konjugata iz bilo kojeg od zahtjeva 1 do 13, naznačena time, što se upotrebljava za izradu lijeka za prevenciju, ublažavanje ili liječenje patologija udruženih sa RAGE, posebno dijabetesa tipa I i/ili tipa II.
The CMV vector for use of claim 8, wherein the promoter is selected form the group consisting of a constitutive promoter, an inducible promoter, a non-viral promoter, and a viral promoter. 
Vektor CMV, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se promotor bira iz skupine koju čine konstitutivni promotor, inducibilni promotor, nevirusni promotor, te virusni promotor.
All test compounds were diluted in 50 nM trisbuffer from DMSO-stocks (2 mM or 10 mM). 
Svi ispitivani spojevi se razrijede sa 50 nM trispuferom iz DMSO-otopine (2 mM ili 10 mM).
A co-crystal of the compound of Formula (IA), according to claim 7, and the co-former molecule 6-hydroxy-2-naphthoic acid. 
Ko-kristal spoja s formulom (IA), prema zahtjevu 7, i ko-formerske molekule 6-hidroksi-2-naftojeve kiseline.
The composition of claim 1 or 2, wherein said poloxamer 188 is present at a concentration of 0.1 mg/ml to 1 mg/ml. 
Pripravak prema zahtjevu 1 ili 2, naznačen time da navedeni poloksamer 188 je prisutan u koncentraciji od 0.1 mg/ml do 1 mg/ml.
A compound according to formula (I) or a a pharmaceutically acceptable salt, thereof: 
Spoj formule (1) ili njegov tautomer, farmaceutski prihvatljiva sol ili njegov solvat:
A closure for a vial or a plunger for a hypodermic syringe according to any one of claims 1 to 3 characterised in that the colourant comprises a pigment or mixture of pigments mixed with a carrier material. 
Zatvarač za bočicu ili klip za potkožnu špricu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, što sredstvo za bojenje sadržava pigment ili mješavinu pigmenata koji su pomiješani s materijalom nosiocem.
an HIC chromatogram in which (i) peak 3 is absent, and (ii) peak 2 represents greater than 95 wt% of the composition; 
HIC kromatogram kod koga je (i) pik 3 odsutan, i (ii) pik 2 predstavlja više od 95 tež% kompozicije;